Beta Drugs Ltd
Beta Drugs Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
5 of 5 strong
The short version
Beta Drugs targets 20% to 25% annual sales growth over the next 3-4 years, aiming to more than double sales to around INR 850-900 crores by 2030. Beta Drugs aims to grow sales at 20% to 25% annually over the next 4 years, targeting INR850-900 crores revenue by 2030 (Page 15).
From Beta Drugs Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Beta Drugs targets 20% to 25% annual sales growth over the next 3-4 years, aiming to more than double sales to around INR 850-900 crores by 2030.
- Export revenues are expected to grow at least 50% in the current year with a medium-term target of reaching INR 200-250 crores by FY28.
- Exports are anticipated to contribute about 30% of total revenue by FY30.
- The cosmetology and dermatology division aims for 30%-40% annual growth for the next 3-4 years.
- The newly acquired Nivian IVF/fertility business is expected to grow at 30% annually over the next 3-4 years.
- Beta plans to launch 20-25 new oncology products over the next 3-4 years to drive branded sales growth of 20%-25%.
- CDMO business aims for steady growth of 5%-6% annually in the coming years.
- Improvement in production capacities and new intermediate API plant commercialization is expected to enhance margins and growth.
Profitability & Margins
See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Beta Drugs invested around INR45 crores last year across three plants, including land purchase for R&D and corporate office which was later dropped in favor of an office building adjacent to current facilities (Page 9).
- The intermediate plant was acquired for INR9 crores with an additional investment of INR15-17 crores; this plant is expected to commercialize by end of this year (Page 9).
- Total planned capex for the next two years is not expected to exceed INR25 crores, primarily towards the intermediate plant (Page 9).
- No major capex planned beyond that, indicating stable capital expenditure outlook (Page 9).
- The company is open to strategic acquisitions if exciting opportunities arise but currently has no options in hand (Page 6).
- The intermediate plant is aimed at reducing dependency on imports and improving margins slightly by 1 to 1.5 basis points when commercialized (Pages 9-10).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of Q1 FY27, Beta Drugs has around 50% of export orders in hand for the upcoming quarter.
- The company expects to fulfill existing orders and is also anticipating new orders and tenders.
- Pending export tenders that were delayed and missed in FY26 have now been awarded in March 2026, with supplies starting from Q1 FY27.
- These delayed tenders had an estimated revenue impact of INR 20-25 crores.
- The company has laid strategies to focus on other high-margin products amid challenges in Platen sales.
- Export orders for the current quarter are expected to be around INR 20-22 crores, with solid growth anticipated in subsequent quarters.
- Overall, the order book visibility is healthy with orders in hand and an expectation of additional new tenders.
Beta Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹94 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Beta Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenteral's (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Beta Drugs Ltd Q4 FY26 results?
Beta Drugs targets 20% to 25% annual sales growth over the next 3-4 years, aiming to more than double sales to around INR 850-900 crores by 2030. Beta Drugs aims to grow sales at 20% to 25% annually over the next 4 years, targeting INR850-900 crores revenue by 2030 (Page 15).
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 62.0 with a market cap of ₹2,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
Beta Drugs invested around INR45 crores last year across three plants, including land purchase for R&D and corporate office which was later dropped in favor of an office building adjacent to current facilities (Page 9).
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.